Conversion

Ref: ISLL:CH:2026 Date: 8th October, 2026 To To Department of Corporate Services, Department of Corporate Services, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor 25th Floor, Dalal Street, Plot No. C/2, G-Block, Mumbai 400 001 Bandra Kurla Complex, Bandra (E), Mumbai 400 051 BSE Scrip Code: 532305 NSE Symbol: INDSWFTLAB Subject: Outcome of the meeting of the Preferential Issue Committee of the Board of Directors of Ind-Swift Laboratories Limited (“the Company”) in accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sir/Ma’am, With reference to the captioned subject and in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we wish to inform that the Preferential Issue Committee of the Board of Directors of Ind-Swift Laboratories Limited (“the Company”), at its meeting held on Thursday, 8th October, 2026, has, inter alia, considered and approved the allotment of 14,00,000 (Fourteen Lakh) Equity Shares of face value of ₹10/- each, upon conversion of 14,00,000 (Fourteen Lakh) Fully Convertible Warrants (“Warrants”), out of the 70,00,000 (Seventy Lakh) Warrants allotted on 17th September, 2026 at an issue price of ₹196/- (Rupees One Hundred and Ninety-Six only) per Warrant, to Essix Biosciences Limited, belonging to the Promoter & Promoter Group, on a preferential basis. The aforesaid conversion has been made upon receipt of the balance 75% consideration of ₹147/- (Rupees One Hundred and Forty-Seven only) per Warrant, aggregating to ₹20,58,00,000/- (Rupees Twenty Crore Fifty-Eight Lakh only). The details of the allotment are as under: S. No. Name of the Allottees Category No. of equity shares allotted pursuant to the conversion of warrants 1. Essix Biosciences Limited Promoter 14,00,000 Total 14,00,000 Consequent to the aforesaid allotment, the paid-up equity share capital of the Company stands increased from ₹86,71,15,580/- (Rupees Eighty-Six Crore Seventy-One Lakh Fifteen Thousand Five Hundred and Eighty only), comprising 8,67,11,558 Equity Shares of face value of ₹10/- each, to ₹86,96,15,580/- (Rupees Eighty-Six Crore Ninety-Six Lakh Fifteen Thousand Five Hundred and Eighty only), comprising 8,69,61,558 Equity Shares of face value of ₹10/- each. Details as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, with respect to the Preferential Allotment is enclosed as Annexure A. The meeting of the Preferential Issue Committee of the Board of Directors commenced at 06:00 P.M. and concluded at 06:15 P.M. This is for your information and records. Thanking you, Yours faithfully, For Ind-Swift Laboratories Limited Pardeep Verma VP-Corporate Affairs & Company Secretary Annexure A S. No. Particulars Disclosures 1. Type of securities proposed to be Equity shares with face value of ₹10/- each issued pursuant to the conversion of warrants. 2. Type of issuance Preferential allotment under Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and other applicable law. 3. Total number of securities proposed Allotment of 14,00,000 equity shares of face to be issued or total amount for which value ₹10/- each, upon s conversion of 14,00,000 the securities will be issued Fully Convertible Warrants (“Warrants”), against the receipt of the balance subscription amount aggregating to ₹20,58,00,000/- (Rupees Twenty Crore Fifty-Eight Lakh only). 4. Name and number of the Investor(s) Name: Essix Biosciences Limited Number: 1 (One) 5. Post allotment of securities- outcome Pursuant to the aforesaid allotment, the issued, of the subscription subscribed and paid-up share capital of the Company stands increased in the manner as set out in the letter above. 6. Issue price / allotted price (in case of Rs. 196/- (Rupees One Hundred and Ninety-Six convertibles) Only) per Equity Share. 7. In case of convertibles - The allottees mentioned above have exercised intimation on conversion of securities their rights and converted their 14,00,000 or on lapse of the tenure of the Warrants instrument 8. Nature of consideration (whether Cash cash or consideration other than cash)